Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat (R) inhaler versus MDI

ZuWallack, R.; De Salvo, M.; Kaelin, T.; Bateman, E.; Park, C.; Abrahams, R.; Fakih, F.; Sachs, P.; Pudi, K.; Zhao, Y.; Wood, C.

doi:10.1016/j.rmed.2010.01.017

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat (R) inhaler versus MDI

Copy For Citation

ZuWallack R., De Salvo M. C., Kaelin T., Bateman E. D., Park C. S., Abrahams R., ...More

RESPIRATORY MEDICINE, vol.104, no.8, pp.1179-1188, 2010 (SCI-Expanded)

Publication Type: Article / Article
Volume: 104 Issue: 8
Publication Date: 2010
Doi Number: 10.1016/j.rmed.2010.01.017
Journal Name: RESPIRATORY MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1179-1188
Keywords: COPD, Respimat (R) inhaler, Ipratropium bromide, Anticholinergic, Bronchodilator, OBSTRUCTIVE PULMONARY-DISEASE, SOFT MIST(TM) INHALER, COMBINATION, ALBUTEROL, AEROSOL, LUNG, FLUTICASONE, PROPIONATE, SALMETEROL, DEPOSITION
Ankara University Affiliated: No

Abstract

We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat (R) inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat (R) inhaler in patients with COPD.